AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

LeWitt, 2008, Levodopa for the treatment of Parkinson's disease, N Eng J Med, 359, 2468, 10.1056/NEJMct0800326 Nutt, 2001, Motor fluctuations and dyskinesia in Parkinson's disease, Parkinsonism Relat Disord, 8, 101, 10.1016/S1353-8020(01)00024-4 Sommer, 2008, What's in the pipeline for the treatment of Parkinson's disease?, Expert Rev Neurother, 8, 1829, 10.1586/14737175.8.12.1829 Christine, 2009, Safety and tolerability of putaminal AADC gene therapy for Parkinson disease, Neurology, 73, 1662, 10.1212/WNL.0b013e3181c29356 Kaplitt, 2007, Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, Lancet, 369, 2097, 10.1016/S0140-6736(07)60982-9 Marks, 2008, Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial, Lancet Neurol, 7, 400, 10.1016/S1474-4422(08)70065-6 Muramatsu, 2010, A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease, Mol Ther, 18, 1731, 10.1038/mt.2010.135 Marks, 2010, Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial, Lancet Neurol, 9, 1164, 10.1016/S1474-4422(10)70254-4 Bevan, 2006, Cellular principles underlying normal and pathological activity in the subthalamic nucleus, Curr Opin Neurobiol, 16, 621, 10.1016/j.conb.2006.10.003 Hamani, 2004, The subthalamic nucleus in the context of movement disorders, Brain, 127, 4, 10.1093/brain/awh029 Wichmann, 2003, Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder, Ann NY Acad Sci, 991, 199, 10.1111/j.1749-6632.2003.tb07477.x Deuschl, 2006, A randomized trial of deep-brain stimulation for Parkinson's disease, N Engl J Med, 355, 896, 10.1056/NEJMoa060281 Weaver, 2009, Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial, JAMA, 301, 63, 10.1001/jama.2008.929 Follett, 2010, Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease, N Engl J Med, 362, 2077, 10.1056/NEJMoa0907083 Levy, 2001, Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms, Brain, 124, 2105, 10.1093/brain/124.10.2105 Emborg, 2007, Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism, J Cereb Blood Flow Metab, 27, 501, 10.1038/sj.jcbfm.9600364 Luo, 2002, Subthalamic GAD gene therapy in a Parkinson's disease rat model, Science, 298, 425, 10.1126/science.1074549 Hughes, 1993, A clinicopathologic study of 100 cases of Parkinson's disease, Arch Neurol, 50, 140, 10.1001/archneur.1993.00540020018011 Fahn, 1987, Unified Parkinson's Disease Rating Scale, 153 Feigin, 2007, Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease, Proc Natl Acad Sci USA, 104, 19559, 10.1073/pnas.0706006104 Tang, 2010, Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis, Lancet Neurol, 9, 149, 10.1016/S1474-4422(10)70002-8 Hutchison, 1998, Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease, Ann Neurol, 44, 622, 10.1002/ana.410440407 Starr, 2002, Implantation of deep brain stimulators into the subthalamic nucleus: technical approach and magnetic resonance imaging-verified lead locations, J Neurosurg, 97, 370, 10.3171/jns.2002.97.2.0370 Zonenshayn, 2004, Location of the active contact within the subthalamic nucleus (STN) in the treatment of idiopathic Parkinson's disease, Surg Neurol, 62, 216, 10.1016/j.surneu.2003.09.039 Tasker, 2004, Commentary, Surg Neurol, 62, 225, 10.1016/j.surneu.2003.11.002 Nelson, 1989, Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet, Clin Neuropharmacol, 12, 91, 10.1097/00002826-198904000-00002 Peto, 1995, The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease, Qual Life Res, 4, 241, 10.1007/BF02260863 Hagell, 1999, Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale, Mov Disord, 14, 448, 10.1002/1531-8257(199905)14:3<448::AID-MDS1010>3.0.CO;2-0 Brown, 1999, Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease, J Geriatr Psychiatry Neurol, 12, 180, 10.1177/089198879901200403 Cummings, 1994, The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia, Neurology, 44, 2308, 10.1212/WNL.44.12.2308 Beck, 1996 Smith, 1982 Stroop, 1935, Studies of interference in serial verbal reactions, J Exptl Psychol, 12, 643, 10.1037/h0054651 Benedict, 1998, Hopkins Verbal Learning Test—Revised: normative data and analysis of inter-form and test-retest reliability, Clin Neuropsychol, 12, 43, 10.1076/clin.12.1.43.1726 Benton, 1994 Shulman, 2010, The clinically important difference on the unified Parkinson's disease rating scale, Arch Neurol, 67, 64, 10.1001/archneurol.2009.295 Pourfar, 2009, Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET, J Neurosurg, 110, 1278, 10.3171/2008.12.JNS08991